Since Roche announced its intention to buy the outstanding shares of Genentech, everbody’s been wondering whether the company’s top scientists will bolt. Genentech put a retention plan in place yesterday — but the main payouts would …
Genentech Inc.'s stock slipped 5.3% on Tuesday as investors winced at news that the U.S. attorney's office in Philadelphia was conducting an investigation into the marketing of the firm's top-selling drug, Rituxan. Shares in the …
Schoellhorn, Friday was named chief executive of Genentech. Genentech stock soared $8.12, to $29.87, and led the New York Stock Exchange active list on volume of 4.4 million shares. The agreement with Roche will be structured as …
Genentech, Inc. (NYSE:DNA) has announced that the biotech giant has authorized the extension of its current stock repurchase program through June 30, 2009 and it amended the current repurchase program. It is increasing the …
Update | 5:51 p.m. Shares of Genentech climbed on Monday afternoon following reports that the biotechnology company was close to a deal to be acquired by Roche Holding for $95 a share. Genentech’s shares rose for a time above …
SAN FRANCISCO — Shares of Genentech plummeted yesterday on news that a once-promising experimental breast-cancer drug had failed a clinical trial. The South San Francisco-based company announced late Monday that Avastin, a …
The offer expired at midnight, New York City time, at the end of Wednesday, March 25. A total of approximately 395.7 million shares of Genentech common stock were tendered representing 84.7% of Genentech’s publicly held shares. …
On August 11 Citigroup maintained a stock rating of “Buy” and lowered the price expectation ... with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, …
Shares of NewLink Genetics Corp. plunged 31% in premarket trade Thursday, putting them on track to open at a more …
Shares of Genentech, the South San Francisco biotech leader, took a pounding yesterday after the firm's Swiss parent said it would sell as much as 17 percent of its stake to provide investors with a greater supply of the much-in-demand …